Upsher-Smith Signs an Agreement with Dr. Reddy’s Laboratories to Acquire its Two Neurology Products

Shots:

• Dr. Reddy’s to receive $70M upfront, $40.5M as milestones, an additional payment including existing contractual obligation and inventory with royalties on sales on a quarterly basis
• Upsher-Smith to get commercialization rights of Dr. Reddy’s Zembrace Symtouch (sumatriptan injection, 3mg) & Tosymra (sumatriptan nasal spray, 10 mg) in the US & other territories              
• Zembrace and Tosymra (DFN-02) are commercialized by Promius Pharma, a subsidiary of Dr. Reddy’s, indicated for the patients with episodic migraine having no benefits with existing therapies

Click here to read full press release/ article | Ref: Dr. Reddy’s | Image: Dr. Reddy’s